Tuesday, June 22, 2-2:30PM EDT
Audience: Quality, Infection Preventionists, Pharmacy, Antimicrobial Stewardship Leaders, Laboratory and Physicians
Since their initial emergency authorization in November, monoclonal antibodies have been an important weapon in the fight against COVID-19. These products have proven to be effective at preventing hospitalization and death due to COVID-19 in some of the highest risk patients.
Alliant Quality is hosting a presentation titled, “Monoclonal Antibody Therapy for High Risk COVID Patients” on June 22 from 2-2:30PM EDT. This presentation will provide an overview of these products, the data behind their emergency authorization, and the clinical considerations around their use.
- Identity and review the currently authorized COVID-19 monoclonal antibody therapies and the requirements associated with their emergency use.
- Demonstrate how the use of monoclonal antibodies can reduce hospitalization and death in those at highest risk for negative outcomes from COVID-19.
- Share tools and resources available to providers and patients interested in monoclonal antibody therapy.
Tim Davis, PharmD, BCNP, PMP
Eastern Region Pharmacist
Division of Public Health, Epidemiology Section
Public Health Preparedness and Response Branch
NC Department of Health and Human Services